CMS'(Centers for Medicare and Medicaid Services) lumbar artificial disc replacement decision prolongs pain for US industry
This article was originally published in Clinica
Executive Summary
The US Centers for Medicare and Medicaid Services' (CMS) denial last week of national coverage for Synthes' lumbar artificial disc replacement, ProDisc-L, will likely have more impact on prospective private usage than for the ostensible CMS target patient group - the over 60s.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.